Drug Approval | June 07, 2022
Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
The drug will be manufactured at the group’s topical facility at Ahmedabad
The drug will be manufactured at the group’s topical facility at Ahmedabad
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Subscribe To Our Newsletter & Stay Updated
